{"id":"saline-nacl-0-9-placebo","safety":{"commonSideEffects":[{"rate":null,"effect":"Minimal adverse events expected (inert placebo)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saline 0.9% is a sterile solution of sodium chloride in water that matches the osmolarity of human blood plasma. It is used clinically for fluid replacement, wound irrigation, and as a vehicle for drug delivery. In clinical trials, it serves as an inert placebo control with no active therapeutic mechanism.","oneSentence":"Normal saline (0.9% NaCl) is an isotonic solution that maintains fluid and electrolyte balance without pharmacological activity, serving as a physiological control or placebo.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:44.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control in clinical trials"},{"name":"Fluid and electrolyte replacement (clinical use)"}]},"trialDetails":[{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT06694701","phase":"PHASE2","title":"Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2025-03-22","conditions":"Sepsis","enrollment":75},{"nctId":"NCT06872060","phase":"NA","title":"The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.","status":"NOT_YET_RECRUITING","sponsor":"Bispebjerg Hospital","startDate":"2026-06-01","conditions":"Kidney Diseases","enrollment":10},{"nctId":"NCT06498063","phase":"NA","title":"The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.","status":"RECRUITING","sponsor":"Ali Asmar","startDate":"2024-02-20","conditions":"Kidney Diseases","enrollment":10},{"nctId":"NCT05435755","phase":"EARLY_PHASE1","title":"Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.","status":"UNKNOWN","sponsor":"Shanghai East Hospital","startDate":"2022-12-02","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT04667637","phase":"PHASE2","title":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol","status":"COMPLETED","sponsor":"Hui-Sheng Chen","startDate":"2021-02-23","conditions":"Stroke, Endovascular Thrombectomy","enrollment":200},{"nctId":"NCT05175781","phase":"NA","title":"Sedation for Non-invasive Ventilation in Blunt Chest Trauma","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2022-01-18","conditions":"Chest Trauma","enrollment":45},{"nctId":"NCT02628444","phase":"PHASE2","title":"Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-05-02","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":1050},{"nctId":"NCT01374516","phase":"PHASE3","title":"Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-06-08","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Dengue","enrollment":20869},{"nctId":"NCT02654080","phase":"PHASE1","title":"Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-03","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT03450915","phase":"PHASE3","title":"A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2018-08-01","conditions":"Influenza","enrollment":12460},{"nctId":"NCT03527355","phase":"PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2018-04-18","conditions":"Typhoid","enrollment":285},{"nctId":"NCT04844996","phase":"EARLY_PHASE1","title":"Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis","status":"COMPLETED","sponsor":"Mersin University","startDate":"2019-09-01","conditions":"Endometriosis","enrollment":18},{"nctId":"NCT00986960","phase":"PHASE2","title":"Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)","status":"WITHDRAWN","sponsor":"University at Buffalo","startDate":"2009-12","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT00897676","phase":"PHASE1, PHASE2","title":"Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity","status":"COMPLETED","sponsor":"Diva De Leon","startDate":"2009-05","conditions":"Congenital Hyperinsulinism","enrollment":17},{"nctId":"NCT02687373","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2016-07-21","conditions":"Malaria","enrollment":337},{"nctId":"NCT03420053","phase":"PHASE1","title":"Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2018-02-07","conditions":"Malaria, Malaria,Falciparum","enrollment":21},{"nctId":"NCT02333591","phase":"PHASE4","title":"Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults","status":"COMPLETED","sponsor":"Mette Zander","startDate":"2016-07","conditions":"Coronary Microvascular Dysfunction","enrollment":25},{"nctId":"NCT02679274","phase":"EARLY_PHASE1","title":"Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2016-02-16","conditions":"Aging","enrollment":3},{"nctId":"NCT01649921","phase":"PHASE3","title":"The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2012-11","conditions":"Sepsis, Septic Shock","enrollment":4},{"nctId":"NCT02115516","phase":"PHASE1","title":"Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":67},{"nctId":"NCT00912496","phase":"PHASE1","title":"Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-06","conditions":"Influenza","enrollment":637}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":112,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo","NaCl","saline","Placebo Comparator"],"phase":"marketed","status":"active","brandName":"Saline (NaCl 0,9 %) (placebo)","genericName":"Saline (NaCl 0,9 %) (placebo)","companyName":"BioTissue Holdings, Inc","companyId":"biotissue-holdings-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Normal saline (0.9% NaCl) is an isotonic solution that maintains fluid and electrolyte balance without pharmacological activity, serving as a physiological control or placebo. Used for Placebo control in clinical trials, Fluid and electrolyte replacement (clinical use).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}